BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

927 related articles for article (PubMed ID: 10873107)

  • 1. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.
    Petersen C; Petersen S; Milas L; Lang FF; Tofilon PJ
    Clin Cancer Res; 2000 Jun; 6(6):2513-20. PubMed ID: 10873107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2.
    Pyo H; Choy H; Amorino GP; Kim JS; Cao Q; Hercules SK; DuBois RN
    Clin Cancer Res; 2001 Oct; 7(10):2998-3005. PubMed ID: 11595687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor.
    Kishi K; Petersen S; Petersen C; Hunter N; Mason K; Masferrer JL; Tofilon PJ; Milas L
    Cancer Res; 2000 Mar; 60(5):1326-31. PubMed ID: 10728694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
    Liu W; Chen Y; Wang W; Keng P; Finkelstein J; Hu D; Liang L; Guo M; Fenton B; Okunieff P; Ding I
    Am J Clin Oncol; 2003 Aug; 26(4):S103-9. PubMed ID: 12902866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations.
    Raju U; Nakata E; Yang P; Newman RA; Ang KK; Milas L
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):886-94. PubMed ID: 12377342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels.
    Shin YK; Park JS; Kim HS; Jun HJ; Kim GE; Suh CO; Yun YS; Pyo H
    Cancer Res; 2005 Oct; 65(20):9501-9. PubMed ID: 16230415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells.
    Wen B; Deutsch E; Eschwege P; De Crevoisier R; Nasr E; Eschwege F; Bourhis J
    J Urol; 2003 Nov; 170(5):2036-9. PubMed ID: 14532848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.
    Ohneseit PA; Krebiehl G; Dittmann K; Kehlbach R; Rodemann HP
    Radiother Oncol; 2007 Feb; 82(2):229-38. PubMed ID: 17207548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
    Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
    FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398.
    Joki T; Heese O; Nikas DC; Bello L; Zhang J; Kraeft SK; Seyfried NT; Abe T; Chen LB; Carroll RS; Black PM
    Cancer Res; 2000 Sep; 60(17):4926-31. PubMed ID: 10987308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
    Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
    Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of poor survival by cyclooxygenase-2 in patients with T4 nasopharyngeal cancer treated by radiation therapy: clinical and in vitro studies.
    Chen WC; McBride WH; Chen SM; Lee KF; Hwang TZ; Jung SM; Shau H; Liao SK; Hong JH; Chen MF
    Head Neck; 2005 Jun; 27(6):503-12. PubMed ID: 15772955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
    Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
    Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
    Liu X; Yue P; Zhou Z; Khuri FR; Sun SY
    J Natl Cancer Inst; 2004 Dec; 96(23):1769-80. PubMed ID: 15572759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis.
    Kang KB; Wang TT; Woon CT; Cheah ES; Moore XL; Zhu C; Wong MC
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):888-96. PubMed ID: 17293239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo.
    Grimes KR; Warren GW; Fang F; Xu Y; St Clair WH
    Oncol Rep; 2006 Oct; 16(4):771-6. PubMed ID: 16969492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
    Spinella F; Rosanò L; Di Castro V; Nicotra MR; Natali PG; Bagnato A
    Clin Cancer Res; 2004 Jul; 10(14):4670-9. PubMed ID: 15269139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.
    Sheng H; Shao J; Morrow JD; Beauchamp RD; DuBois RN
    Cancer Res; 1998 Jan; 58(2):362-6. PubMed ID: 9443418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells.
    Souza RF; Shewmake K; Beer DG; Cryer B; Spechler SJ
    Cancer Res; 2000 Oct; 60(20):5767-72. PubMed ID: 11059772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
    Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
    Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.